 Home > Active Ingredient News > Drugs Articles > The revenue of the three unprofitable pharmaceutical companies in 2021 will soar by 94,407.79%!

The revenue of the three unprofitable pharmaceutical companies in 2021 will soar by 94,407.79%!

 Last Update: 2022-04-29
 Source: Internet
 Author: User

Tags

flower drug

2 4 toxicity

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Introduction: As of March 20, 2022, more than 240 A-share listed pharmaceutical companies have successively released their 2021 annual reports, performance forecasts or express reports
.

Among the "work achievements" of many pharmaceutical companies, three pharmaceutical companies that were previously unprofitable on the Science and Technology Innovation Board have turned losses into profits: Bio-Thera achieved operating income of 829 million yuan, a year-on-year increase of 348.

Three listed pharmaceutical companies are expected to get "U" on the Science and Technology Innovation Board

Among the more than 240 A-share listed pharmaceutical companies that have published corporate annual reports, performance forecasts or express reports, there are three notable pharmaceutical companies that have not made profits on the Science and Technology Innovation Board before, and achieved explosive profits for the first time in 2021, thus turning losses into profits.

.

The three pharmaceutical companies are: Bio-Thera, CanSino and Ellis

The special symbol "U" of the Science and Technology Innovation Board is specified in the Shanghai Stock Exchange's "Notice on Matters Related to the Trading of Stocks and Depository Receipts on the Science and Technology Innovation Board": if the issuer has not made a profit, the special symbol of its stocks or depositary receipts is "U" ”; if the issuer realizes profit for the first time, the special mark will be cancelled
.

Since the opening of the STAR Market in July 2019, 12 unprofitable biotech companies have been listed on the STAR Market (Table 1)

Table 1 Information on 12 Biotechs listed on the Science and Technology Innovation Board in 2020

Data source: Flush Network | Tabulation: Bio-Exploration Editorial Team

As of March 21, 2022, according to the market value statistics of 12 unprofitable biotech companies, it is found that there are various degrees of decline (Table 2)
.

In this regard, Mr.

Table 2 Changes in market value of 12 Biotechs listed on the Science and Technology Innovation Board in 2020

Data source: Flush Network | Tabulation: Bio-Exploration Editorial Team

Why did the three IPOs on the Science and Technology Innovation Board achieve outstanding results?

The three companies that will turn losses into profits in 2021 will all complete the IPO on the Science and Technology Innovation Board in 2020.
Why are they able to deliver such dazzling results? The answer is in their recently released 2021 annual performance bulletin
.

01.
Biota

Bio-Tech Bio-Pharmaceutical Co.
, Ltd.
, established in 2003, is an innovative bio-pharmaceutical enterprise focusing on the research and development of innovative drugs and biosimilars
.

The company adheres to the concept of "innovation only for life", adheres to the innovation-driven development strategy, and is committed to developing a new generation of innovative drugs and biosimilars for the treatment of tumors, autoimmune diseases, cardiovascular diseases and other major diseases that endanger human life or health.

Figure 1 Bio-Tech's product pipeline (Source: Bio-Tech's prospectus [1])

According to Bio-Tech's 2021 annual performance bulletin announcement, the company's operating income was 828.
8315 million yuan, a year-on-year increase of 348.
04%; the company's net profit attributable to the owner of the parent company was 85.
1785 million yuan, deducting non-recurring gains and losses attributable to the owner of the parent company The net profit was 39.
1653 million yuan, compared with the same period of the previous year, it turned losses into profits; the company's basic earnings per share was 0.
21 yuan, and the weighted average return on net assets was 4.
16%[2]
.

During the reporting period, the operating performance turned losses into profits, mainly due to the following reasons:

1.
During the reporting period, based on the domestic market and facing the global market, the company actively expanded more global market shares and reached commercial cooperation with many enterprises at home and abroad
.

Among them, a licensing and commercialization agreement was signed with Biogen International GmbH for BAT1806 (tocilizumab injection), and the milestone conditions agreed in the agreement were completed; The "Drug Registration Certificate" approved by the Drug Administration has reached the milestone conditions in the licensing and commercialization agreement signed with BeiGene Co.

2.
During the reporting period, the company actively expanded the domestic market.
The business scale of the drug Geleli® (adalimumab injection) gradually expanded, and the sales revenue increased steadily
.

02.
CanSino

Founded in 2009, CanSino Biologics Co.
, Ltd.
is an innovative vaccine company dedicated to R&D, production and sales
.

Under the leadership of a group of senior scientists in the field of vaccines and senior technical experts with years of experience in large international pharmaceutical companies, CanSino has rapidly advanced the research and development of a series of domestic innovative vaccines

Relying on the innovation of scientific research, CanSino was listed on the H-shares of the main board of the Hong Kong Stock Exchange in March 2019; CanSino was officially listed on the Science and Technology Innovation Board in August 2020
.

Figure 2 The development history of CanSino (Information source: CanSino Prospectus [3] | Drawing: Bio-Exploration Editorial Team)

According to the announcement of CanSino’s 2021 annual performance report, the company achieved operating income of 4,299,702,300 yuan, a year-on-year increase of 17,174.
54%; realized a net profit attributable to owners of the parent company of 1,914,390,000 yuan; realized non-recurring gains and losses attributable to owners of the parent company The net profit was 1,797,037,700 yuan, turning losses into profits
.

At the end of the reporting period, the company's total assets were 11,874,187,000 yuan, a year-on-year increase of 75.

The main reasons for the increase or decrease of the relevant items are more than 30%:

1.
During the reporting period, the company's total operating income, operating profit, total profit, net profit attributable to owners of the parent company, net profit attributable to owners of the parent company after deducting non-recurring gains and losses, basic earnings per share and weighted average The substantial change in the return on net assets was mainly due to the fact that the recombinant novel coronavirus vaccine (type 5 adenovirus vector) (trade name: Keweisha) obtained the conditional marketing approval and emergency use authorization from many countries at home and abroad.
The commercialization of the company has a positive impact on the company's total operating income and related profit indicators
.

2.
At the end of the reporting period, the company's total assets increased by 75.
96% year-on-year, mainly due to the increase in current assets such as monetary funds, accounts receivable and inventories brought about by the growth of the company's revenue during the reporting period, as well as the increase in prepayments; Scale, non-current assets such as fixed assets and construction in progress increased
.

3.
At the end of the reporting period, the company's owners' equity attributable to the parent company increased by 31.
70% year-on-year, and the net assets per share attributable to owners of the parent company increased by 31.
72% year-on-year, mainly due to the company's turnaround from losses to profits and the increase in net profit from operations.
increased undistributed profits
.

03.
Alice

Ailes Medical Technology Co.
, Ltd.
is an innovative drug company focusing on the field of oncology.
Through many successful strategic transformations, it has accumulated excellent research and development capabilities in the field of small molecule targeted drugs for lung cancer and built a rich clinical pipeline.
(Figure 3)
.
On March 3, 2021, the company's self-developed third-generation EGFR-TKI fumetinib was approved for marketing
.

Figure 3 The development history of Ailes (Information source: Ailes prospectus [5] | Drawing: Bio-Exploration editorial team)

According to the 2021 annual performance report of Ailes, the company achieved operating income of 530.
0942 million yuan, a year-on-year increase of 94,407.
79%; net profit attributable to owners of the parent company was 18.
2746 million yuan, a year-on-year turnaround; deductions attributable to owners of the parent company The net profit of non-recurring gains and losses was -62,042,300 yuan, and the loss narrowed sharply
.

Allis achieved an annual operating income of 530 million yuan, mainly from the sales revenue of fumetinib mesylate tablets (trade name: Evsa) and the recognition of related revenue from overseas authorized transactions
.
Fumetinib has been approved for marketing since March 2021, and the annual sales revenue has reached 236 million yuan, and the related revenue from overseas authorized transactions totaled 294 million yuan
.
As of the end of the reporting period, it has covered 30 provinces and cities, nearly 800 hospitals and about 250 DTP pharmacies
.
In December 2021, fumetinib was officially included in the national medical insurance catalog through negotiation, and it has been successfully included in the inclusive commercial supplementary medical insurance in 47 cities[6]
.

It is not difficult to see that growing companies at the forefront of technology and possessing key core technologies are the focus of the Sci-tech Innovation Board
.
In the post-epidemic era, more innovative products are needed to achieve the sustainable development of technology-based companies
.

References:

[1] Prospectus of Bio-Tech Biopharmaceutical Co.
,
Ltd.
http://static.
sse.
com.
cn/stock/information/c/201907/8842a07bb13541918cb9f2122b045fec.
pdf

[2] Announcement of the 2021 Annual Results Express of Bio-Tech Biopharmaceutical Co.
,
Ltd.
http://notice.
10jqka.
com.
cn/api/pdf/ff6daf9e9f4152ed.
pdf

[3] Prospectus of CanSino Biological Co.
,
Ltd.
https://pdf.
dfcfw.
com/pdf/H2_AN202002031374675296_1.
pdf

[4] CanSino: 2021 Annual Results Announcement
.
http://vip.
stock.
finance.
sina.
com.
cn/corp/view/vCB_AllBulletinDetail.
php?stockid=688185&id=7852664

[5] Prospectus of Shanghai Alys Pharmaceutical Technology Co.
,
Ltd.

http://static.
sse.
com.
cn/stock/information/c/202004/2c06ee20e91c4b67b9cd3d503564712b.
pdf

[6] Announcement of the 2021 Annual Results Express of Shanghai Ailes Pharmaceutical Technology Co.
,
Ltd.
http://file.
finance.
sina.
com.
cn/211.
154.
219.
97:9494/MRGG/CNSESH_STOCK/2022/2022-2/2022-02-26/7852595.
PDF

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.